N-(4-amino-phenyl)-4-fluoro-2-trifluoromethyl-benzamide | 1186377-30-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-amino-phenyl)-4-fluoro-2-trifluoromethyl-benzamide
• 英文别名: N-(4-Aminophenyl)-4-fluoro-2-trifluoromethyl-benzamide；N-(4-aminophenyl)-4-fluoro-2-(trifluoromethyl)benzamide
• CAS: 1186377-30-9
• 化学式: C₁₄H₁₀F₄N₂O
• 分子量: 298.24
• InChiKey: QYAKZKZDJPNJNR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-(4-amino-phenyl)-4-fluoro-2-trifluoromethyl-benzamide 、 10-chloro-6,10b-dihydro-2H-oxazolo[3,2-c]pyrido[3,2-e]pyrimidin-5(3H)-one 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 生成 4-fluoro-N-(4-(5-oxo-3, 5,6,10b-tetrahydro-2H-oxazolo[3,2-c]pyrido[3,2-e]pyrimidin-10-ylamino)phenyl)-2-(trifluoromethyl)benzamide
  参考文献：
  名称：

  NOVEL BICYCLIC UREA COMPOUNDS

  摘要：

  该发明提供了根据公式（I）提供的新型取代的氮杂杂环化合物，其制备及用于治疗高增殖性疾病，如癌症。

  公开号：

  US20120190654A1
• 作为产物：
  描述：

  在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 N-(4-amino-phenyl)-4-fluoro-2-trifluoromethyl-benzamide
  参考文献：
  名称：

  SAR and evaluation of novel 5H-benzo[c][1,8]naphthyridin-6-one analogs as Aurora kinase inhibitors

  摘要：

  Several potent Aurora kinase inhibitors derived from 5H-benzo[c][1,8]naphthyridin-6-one scaffold were identified. A crystal structure of Aurora kinase A in complex with an initial hit revealed a binding mode of the inhibitor within the ATP binding site and provided insight for structure-guided compound optimization. Subsequent SAR campaign provided a potent and selective pan Aurora inhibitor, which demonstrated potent target modulation and antiproliferative effects in the pancreatic cell line, MIAPaCa-2. Furthermore, this compound inhibited phosphorylation of histone H3 (pHH3) in mouse bone morrow upon oral administration, which is consistent with inhibition of Aurora kinase B activity. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.03.008

文献信息

• [EN] PROTEIN KINASE INHIBITORS AND USE THEREOF<br/>[FR] INHIBITEURS DE PROTÉINE KINASE ET LEUR UTILISATION
  申请人：MERCK SERONO SA

  公开号：WO2009108670A1

  公开（公告）日：2009-09-03

  Disclosed are benzonaphthyridinyl derivative compounds and analogs thereof, pharmaceutical compositions comprising such compounds and processes for preparing the same. The compounds are useful in the treatment of diseases amenable to kinase signal transduction inhibition, regulation or modulation.

  揭示了苯并萘啶衍生物化合物及其类似物，包括含有这些化合物的药物组合物以及制备这些化合物的方法。这些化合物在治疗对激酶信号传导抑制、调节或调控敏感的疾病中很有用。
• [EN] C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF<br/>[FR] INHIBITEURS DE PROTÉINES KINASES DE TYPE BENZONAPHTYRIDINONES TRICYCLIQUES MODIFIÉES SUR LE NOYAU C ET LEUR UTILISATION
  申请人：MERCK PATENT GMBH

  公开号：WO2010077530A1

  公开（公告）日：2010-07-08

  Disclosed are C-ring modified tricyclic benzonaphthiridinone compounds and analogs thereof, pharmaceutical compositions comprising such compounds and processes for preparing the same. The compounds are useful in the treatment of diseases amenable to protein kinase signal transduction inhibition, regulation and/or modulation.

  本文披露了C环修饰的三环苯并萘啶酮化合物及其类似物，包括含有这些化合物的药物组合物以及其制备方法。这些化合物在治疗易于蛋白激酶信号传导抑制、调节和/或调节的疾病中有用。
• PROTEIN KINASE INHIBITORS AND USE THEREOF
  申请人：Huck Bayard R.

  公开号：US20110053906A1

  公开（公告）日：2011-03-03

  Disclosed are benzonaphthyridinyl derivative compounds and analogs thereof, pharmaceutical compositions comprising such compounds and processes for preparing the same. The compounds are useful in the treatment of diseases amenable to kinase signal transduction inhibition, regulation or modulation.

  本发明揭示了苯并萘啉衍生物化合物及其类似物，包括含有这些化合物的制药组合物和制备这些化合物的过程。这些化合物可用于治疗易于激酶信号传导抑制、调节或调控的疾病。
• NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS
  申请人：Xiao Yufang

  公开号：US20110269758A1

  公开（公告）日：2011-11-03

  Naphthyridinone derivative compounds that inhibit Aurora kinase enzymes are disclosed along with pharmaceutical compositions comprising these compounds and methods for synthesizing the same. Such compounds have utility in the treatment of proliferative diseases resulting from unregulated and/or disturbed Aurora kinases such as cancers, psoriasis, viral and bacterial infections, inflammatory and autoimmune diseases.

  本发明揭示了抑制Aurora激酶酶的萘啶酮衍生物化合物，以及包含这些化合物的制药组合物和合成这些化合物的方法。这些化合物在治疗由未调节和/或扰动的Aurora激酶引起的增殖性疾病中具有实用性，如癌症、银屑病、病毒和细菌感染、炎症性和自身免疫性疾病。
• C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof
  申请人：Xiao Yufang

  公开号：US20110312951A1

  公开（公告）日：2011-12-22

  Disclosed are C-ring modified tricyclic benzonaphthiridinone compounds and analogs thereof, pharmaceutical compositions comprising such compounds and processes for preparing the same. The compounds are useful in the treatment of diseases amenable to protein kinase signal transduction inhibition, regulation and/or modulation.

  本发明涉及C环修饰的三环苯并那敏酮化合物及其类似物、包含这些化合物的制药组合物和制备这些化合物的方法。这些化合物在治疗易受蛋白激酶信号转导抑制、调节和/或调控的疾病方面是有用的。